Study With Improved Solubility Pazopanib

• Status: Completed
• Trial end date: 2017-08-28
• Target enrollment: 0
• Participant gender: All

Summary

The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Netherlands Cancer Institute

Criteria

Inclusion Criteria:

• Locally advanced or metastatic cancer;

• Able and willing to give written consent;

• WHO performance status of 0, 1 or 2;

• Able and willing to undergo blood sampling for PK analysis;

• Minimal acceptable safety laboratory values;

• Negative pregnancy test for female patients with childbearing potential;

• Able and willing to swallow oral medication.

Exclusion Criteria:

• Any treatment with investigational drugs within 30 days prior to receiving the investigational treatment;

• Any treatment with CYP3A4, BCRP or PGP interfering drugs;

• Patients who received treatment with Votrient(R) kess than 1 week ago;

• Woman who are pregnant or breast feeding;

• Patients suffering from any known condition that may influence the dissolution or absorption of Pazopanib.